Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -28.00 | 53.75 | 274.55 | — | — | — | — | — | — | — | 6.78 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 7.84 | 5.48 | 3.62 | 4.36 | 5.24 | 5.95 | 4.80 | 5.47 | 4.91 | 5.74 | 3.41 | 7.73 | 7.62 | 17.57 | 32.94 | 41.22 | — | — | — | — | — |
| — | -7.9% | -24.6% | -20.4% | +6.7% | +3.6% | +40.9% | -29.2% | -35.7% | -67.3% | -89.7% | -81.2% | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 8.22 | 9.23 | 5.80 | 6.77 | — | — | — | — | — | — | 114.71 | — | — | — | — | — | 75.47 | 17.02 | 11.63 | 7.26 | 12.89 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +485.7% | +100.1% | +79.6% | +19.4% | +159.0% | |
| P/FCF | — | 1958.11 | 22.97 | — | 43.71 | — | — | — | — | — | 2.21 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 49.68 | — | — | — | — | — | — | — | — | 5.63 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 50.43 | 214.47 | — | — | — | — | — | — | — | 5.87 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.6% | 96.0% | 96.2% | 87.2% | 94.7% | 90.0% | 95.7% | 91.6% | 80.5% | 91.6% | 97.8% | 93.0% | 94.9% | 95.5% | 94.3% | 94.4% | — | — | — | — | — |
| — | +6.7% | +0.5% | -4.8% | +17.6% | -1.8% | -2.1% | -1.5% | -15.1% | -4.1% | +3.7% | -1.5% | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -14.2% | 9.7% | -0.8% | -18.7% | -1.6% | -28.3% | -9.4% | -12.1% | -74.9% | -69.4% | 54.2% | -18.7% | -15.6% | -140.3% | -314.3% | -399.7% | — | — | — | — | — |
| — | +134.3% | +91.6% | -54.8% | +97.8% | +59.2% | -117.3% | +35.2% | -379.8% | +50.6% | +117.2% | +95.3% | — | — | — | — | — | — | — | — | — | |
| Net Margin | -21.8% | 11.0% | 1.3% | -34.7% | -5.1% | -32.7% | -13.3% | -25.0% | -82.2% | -76.5% | 50.6% | -27.6% | -28.7% | -163.7% | -360.9% | -446.7% | — | — | — | — | — |
| — | +133.8% | +110.0% | -38.7% | +93.8% | +57.3% | -126.3% | +9.1% | -187.0% | +53.3% | +114.0% | +93.8% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -66.8% | 4.9% | 0.5% | -30.9% | — | — | — | — | — | -670.2% | 425.9% | — | — | — | — | -5885.8% | -142.6% | -48.2% | -26.1% | -25.5% | -20.3% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -23023.9% | -603.7% | -184.1% | -49.0% | -136.8% | -10.0% | |
| ROA | -16.9% | 2.7% | 0.3% | -8.0% | -1.4% | -6.9% | -2.6% | -3.8% | -9.4% | -8.4% | 26.7% | -11.7% | -9.7% | -26.4% | -24.8% | -23.9% | -35.2% | -29.2% | -17.8% | -18.3% | -15.5% |
| — | +138.7% | +111.1% | -109.1% | +85.6% | +17.7% | -109.5% | +67.3% | +3.2% | +68.2% | +207.7% | +51.1% | +72.4% | +9.7% | -39.6% | -30.8% | -127.5% | -104.3% | -11.3% | -84.9% | +8.5% | |
| ROIC | — | 109.2% | — | — | — | — | — | — | — | — | — | -31.0% | -44.4% | -6249.1% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | 10.41 | — | — | — | — | — | 8.81 | 0.58 | 0.40 | 0.32 | 0.26 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +3259.2% | +161.1% | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 2.17 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.34 | 5.85 | 6.98 | 6.37 | 4.69 | 4.85 | 5.13 | 6.38 | 7.80 | 8.02 | 6.93 | 3.56 | 4.84 | 5.12 | 5.39 | 5.80 | 10.30 | 5.12 | 8.96 | 13.54 | 12.90 |
| — | +20.7% | +35.9% | -0.0% | -39.8% | -39.6% | -25.9% | +79.3% | +61.0% | +56.8% | +28.6% | -38.7% | -53.0% | -0.1% | -39.8% | -57.2% | -20.1% | -84.5% | -6.9% | +1.1% | +9.2% | |
| Quick Ratio | 6.19 | 5.66 | 6.78 | 6.23 | 4.44 | 4.59 | 4.97 | 6.22 | 7.64 | 7.75 | 6.72 | 3.27 | 4.39 | 4.74 | 5.16 | 5.67 | 10.30 | 5.12 | 8.96 | 13.54 | 12.90 |
| — | +23.4% | +36.6% | +0.0% | -41.9% | -40.8% | -26.1% | +90.3% | +74.0% | +63.6% | +30.2% | -42.4% | -57.4% | -7.5% | -42.4% | -58.1% | -20.1% | -84.5% | -6.9% | +1.1% | +9.2% | |
| Interest Coverage | -3.63 | 579.00 | 29.71 | -14.20 | -0.09 | -4.15 | -0.95 | -0.68 | -4.60 | -4.23 | 13.41 | -1.93 | -1.18 | -5.08 | -6.58 | -7.50 | -66.97 | -88.74 | -62.72 | — | -75.61 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FENC stock.
Fennec Pharmaceuticals Inc.'s current P/E is -28.0x. The average P/E over the last 2 quarters is 164.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Fennec Pharmaceuticals Inc.'s current operating margin is -14.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Fennec Pharmaceuticals Inc.'s business trajectory between earnings reports.